Neuroendocrine Tumor Treatment Market Size is Estimated to Value $3.33 Billion By 2025: Grand View Research, Inc

 Breaking News
  • No posts were found

Neuroendocrine Tumor Treatment Market Size is Estimated to Value $3.33 Billion By 2025: Grand View Research, Inc

August 08
10:28 2019
Neuroendocrine Tumor Treatment Market Size is Estimated to Value $3.33 Billion By 2025: Grand View Research, Inc

Grand View Research, Inc. – Market Research And Consulting
According to report published by Grand View Research, The global neuroendocrine tumor treatment market size was estimated at USD 1.51 billion in 2017 and is expected to register a CAGR of 10.4% during the forecast period.

The global Neuroendocrine Tumor (NET) Treatment Market size is expected to reach USD 3.33 billion by 2025, according to a new report by Grand View Research, Inc. The market is estimated to register a CGAR of 10.4% during the forecast period. Increasing pervasiveness of carcinoid tumors is expected to drive the market over the forecast period. Heavy investment in clinical trials by various pharmaceutical companies to develop novel products is another factor propelling the market development.

For instance, Novartis AG has the highest number of clinical trials followed by Pfizer Inc. and Ipsen Pharma. Moreover, technological advancements in therapies to treat neuroendocrine tumors are anticipated to fuel the market growth over the coming years. Some of these include PET imaging with Ga labeled Somatostatin, targeted drug therapies, and tyrosine kinase therapies. For instance, Lutathera by Novartis AG received FDA approval for the first ever radionucleotide therapy.

U.S. neuroendocrine tumor treatment market size, by product, 2014 - 2025 (USD Million)


Request a Sample Copy of the Global Neuroendocrine Tumor Treatment Research Report @ https://www.grandviewresearch.com/industry-analysis/neuroendocrine-tumor-net-treatment-market/request/rs1

Further key findings from the study suggest:

  • Somatostatin analogs segment accounted for the largest revenue share of more than 60% in 2017 owing to its cost-effective and safe therapy procedure
  • The pancreas segment is expected to exhibit the highest growth in the neuroendocrine tumor treatment market over the forecast period
  • Clinics segment is expected to register the highest CAGR of 10.9% over the estimated period due to increasing patient preference for clinics over other healthcare settings
  • North America held the largest share of the global neuroendocrine tumor treatment market in 2017 mainly due to favorable government insurance policies
  • Some of the key companies in the global market are Pfizer, Inc.; Novartis AG; Ipsen Pharma; and Boehringer Ingelheim International GmbH. Major companies focus more on R&D to develop novel therapeutics for NETs.

 Global neuroendocrine tumor treatment market share, by end use, 2017 (%)


Have Any Query? Ask Our [email protected] https://www.grandviewresearch.com/inquiry/5490/ibb

Grand View Research has segmented the global neuroendocrine tumor treatment market on the basis of product, site, end use, and region:

NET Treatment Product Outlook (Revenue, USD Million, 2014 – 2025)

  • Somatostatin Analogs (SSAs)
  • Targeted Therapy
  • Others

NET Treatment Site Outlook (Revenue, USD Million, 2014 – 2025)

  • Lungs
  • Pancreas
  • Colon
  • Small Intestine
  • Others

NET Treatment End-use Outlook (Revenue, USD Million, 2014 – 2025)

  • Hospitals
  • Clinics
  • Others

NET Treatment Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
  • Asia Pacific
    • China
    • India
  • Latin America
    • Mexico 
    • Brazil
  • Middle East & Africa
    • South Africa

Browse Related Category @

Migraine Drugs Market: Increased uptake of novel drug classes, launch of Calcitonin gene-related peptide (CGRP)-based therapies, and high unmet needs are some of the key factors driving market growth.

Central Nervous System (CNS) Therapeutic Market: Advancements in diagnostics, therapeutics, and drug discovery techniques are primarily driving the growth of the market. 

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: www.grandviewresearch.com/industry-analysis/neuroendocrine-tumor-net-treatment-market